Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults

Despite repeated malaria infection, individuals living in areas where malaria is endemic remain vulnerable to reinfection. The Janus kinase (JAK1/2) inhibitor ruxolitinib could potentially disrupt the parasite-induced dysfunctional immune response when administered with antimalarial therapy. This ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Chughlay, M. Farouk, Barnes, Karen I., El Gaaloul, Myriam, Abla, Nada, Möhrle, Jörg J., Griffin, Paul, van Giersbergen, Paul, Reuter, Stephanie E., Schultz, Hayley B., Kress, Anita, Tapley, Peter, Webster, Rebecca A., Wells, Timothy, McCarthy, James S., Barber, Bridget E., Marquart, Louise, Boyle, Michelle J., Engwerda, Christian R., Chalon, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765294/
https://www.ncbi.nlm.nih.gov/pubmed/34694880
http://dx.doi.org/10.1128/AAC.01584-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765294/
https://www.ncbi.nlm.nih.gov/pubmed/34694880
http://dx.doi.org/10.1128/AAC.01584-21

Ejemplares similares